





WINTER 2021
VIRTUAL MEETING
Jan. 28 - 30, 2021

Program Book

#NRG2021



NON CME



Welcome to the NRG Oncology Virtual Winter Meeting 2021

As we host our second “pandemic edition” virtual meeting, the occasion marks over 10 months since we – and all our Members, have added social distancing and remote work to our everyday lives. Where once we gathered in conference rooms and ballrooms, we now navigate meetings from our cubical or home office, safely distanced from others. With many of us already having received at least our first dose of the vaccine, a light shines at the end of the tunnel as we look ahead toward gathering once again.

Eventually, the pandemic will become just a memory, but some of what we have learned - such as the use of technology to make some of our in-person meetings accessible to those who cannot travel - will remain. Certainly, there are other positive outcomes as well – the widespread adopting of telehealth and remote tools for interacting with patients among them. We appreciate the efforts of NRG Members to continue this important work, and our accomplishments of 2020 reflect this devotion.

In the meantime, we welcome you to the first NRG Oncology Group meeting of 2021! We hope you will join us for many sessions that capture your interests and take advantage of some of the virtual tools to connect with colleagues and friends. Don’t be shy on social media, we’d love to hear how things are going! Use our hashtag #NRG2021 to follow our meeting as it progresses.

Our General Session is a forum to learn more about our Group’s activities, and especially to honor our friend Wally Curran, Jr., MD as he has stepped down as NRG Oncology Group Chair. The Thursday Plenary offers some thoughts about leveraging funding opportunities in addition to highlighting the work of a few of our committees – we hope you will enjoy this session as well.

As always, we appreciate all you do on NRG Oncology’s behalf and wish a safe and healthy 2021. Please enjoy the meeting.



M Machtay

Mitchell Machtay, MD
Presiding Group Chair (*Interim*)



Robert S. Mannel, MD

Robert S. Mannel, MD
NRG Group Chair
& Board Chairman



N Wolmark

Norman Wolmark, MD
NRG Group Chair
& Contact PI

NRG ONCOLOGY MISSION STATEMENT

NRG Oncology seeks to improve the lives of cancer patients by conducting practice-changing multi-institutional clinical and translational research with emphases on gender-specific malignancies including gynecologic, breast, and prostate cancers and on localized or locally advanced cancers of all types.

For the Educational Objectives, we list the following:

- Inform the participants of the current state of clinical and basic oncologic research, particularly, but not exclusively as it relates to clinical trials.
- Provide participants with peer review critiques of progress (or lack of it) with the objective of self-improvement.
- Provide an opportunity to learn research administration and financial management in a cooperative group setting.
- Provide a forum for experts from diverse fields to improve research practices and patient management.





Amanda Rivera, MD
@AmandaRiveraMD



Mohamed E. Salem, MD
@SalemGIOncDoc



Chirag Shah, MD
@CShahMD



Nicole L. Stout, DPT, FAPTA
@NicoleStoutPT



Samilia Obeng-Gyasi, MD, MPH
@GyasiSamilia

#NRG2021



WINTER 2021
VIRTUAL MEETING
Jan. 28 - 30, 2021

Follow our Winter Meeting

NRG Social Media Ambassadors



Stay connected virtually with updates and announcements from the NRG Oncology Winter 2021 Virtual Meeting on Twitter and Facebook



#NRG2021



<https://www.facebook.com/nrgoncology/>



The NRG Oncology Winter 2021 Virtual Meeting

WEDNESDAY, JANUARY 27, 2021

- 1:00** Protocol Support Committee Presents - "Introduction to Clinical Trials: Principals of NRG Oncology Clinical Trials Management for Nurses and Clinical Research Associates"
- 3:00** NRG FORTE Study Update

THURSDAY, JANUARY 28, 2021

- 10:00** Health Disparities Committee
- 10:00** Protocol Support Committee Presents - "Clinical Trial Nurse/Clinical Research Associate Workshop" - Continuing Education Session
- 10:30** New Investigator Committee Presents - "LOI/Concept Development Nuts and Bolts"
- 12:30** New Investigators Networking Luncheon BYOL
- 1:00** Protocol Support Committee Presents - "Clinical Trial Nurse/Clinical Research Breakout Sessions"
- 1:00** Cancer Prevention & Control Committee
- 3:00** Plenary Keynote
- 4:00** Winter Symposium - "Survivorship: Surviving & Thriving in the Shadow of Cancer"
- 4:00** Patient Centered Outcomes Research Committee

FRIDAY, JANUARY 29, 2021

- | | |
|--|---|
| 8:00 Developmental Therapeutics Committee | 1:30 Cancer Care Delivery Research Committee |
| 8:00 Rare Tumor Subcommittee | 1:30 Head and Neck Cancer Committee |
| 8:00 Radiation Oncology Committee | 1:30 Genitourinary Cancer Committee |
| 10:00 NCORP Townhall | 1:30 Uterine Corpus Cancer Subcommittee |
| 10:00 Brain Tumor Committee | 3:30 Translational Science Committee |
| 10:00 Breast Cancer Committee | 3:30 Patient Advocate Committee |
| 10:00 Cervix/Vulvar Cancer Subcommittee | 3:30 Ovarian Cancer Subcommittee |
| 12:15 General Session | |

SATURDAY, JANUARY 30, 2021

- 9:00** Gastrointestinal Colorectal Cancer Committee
- 9:00** Lung Cancer Committee
- 9:00** Gynecologic Cancer Committee

10:45 Gastrointestinal Non-Colorectal Cancer Committee

NRG Oncology Virtual Meeting - July 2020





**We are committed more
than ever to making a
difference in the lives of
cancer patients.**



seagen.com



Special Events/Sessions/Workshops



FORTE Protocol Workshop

Wednesday, January 27, 2021

3:00 pm - 4:00 pm EST



WINTER 2021
VIRTUAL MEETING
Jan. 28 - 30, 2021

#NRG2021



Lisa Kachnic, MD

Dr. Lisa Kachnic is the chief of Radiation Oncology Service at the New York-Presbyterian/Columbia University Irving Medical Center and Chair of the Department of Radiation Oncology at Columbia University. She currently serves as the Associate Chair for NRG NCORP and Co-Chair of NRG's Cancer Prevention and Control Committee.

Dr. Kachnic is one of the nation's leading radiation oncologists and her combined focus on clinical excellence, technological innovation and patient centered research continues to advance the field of radiation oncology.



Robert E. Schoen, MD, MPH

Dr. Schoen is a Professor of Medicine and Epidemiology and Chief of Gastroenterology, Hepatology and Nutrition at the at the University of Pittsburgh and UPMC.

Dr. Schoen is the Principal Investigator of the FORTE trial and an international expert in early detection and prevention of colorectal cancer.



Jeffrey Dueker, MD

Dr. Dueker is an Assistant Professor of Medicine in the Division of Gastroenterology at the University of Pittsburgh Medical Center (UPMC) and the protocol co-chair for the FORTE trial. His research interests are in quality improvement and healthcare delivery models.



Sarah Camden, MS

Sarah Camden is an Assistant Project Manager at the Statistics and Data Management Center of NRG Oncology – Pittsburgh. Her specialty is using Medidata Rave to capture data elements for breast, colorectal, and gynecologic cancer trials. She will be serving as the Study Builder and Data Manager for the FORTE trial.



Christine Lorson, BSN, RN

Christine Lorson is an Education and Communication Specialist with FORTE trial. Christine is a graduate of the University of Pittsburgh with thirty years of professional nursing experience. Christine will be contributing to the success of FORTE through site engagement, communications, and education.



FORTE Protocol Workshop Agenda

Date: January 27, 2021

Time: 3:00 p.m. – 4:00 p.m. EST

Location: Remote at NRG Winter Meeting

3:00 p.m.-3:05 p.m.	Welcome	TBD/ Lisa Kachnic, MD, NRG NCORP Associate Chair
3:05 p.m.-3:35 p.m.	Part I: FORTE Introduction 1. Introduction and importance of FORTE 2. Trial overview and eligibility 3. Retrospective Enrollment/ Patient selection Questions and Answers	Robert Schoen, MD, MPH, Principal Investigator/ Study Chair Jeffrey Dueker, MD, Protocol Co-chair Joshua E. Melson, MD
3:35 p.m.-3:45 p.m.	Part II: FORTE Site Resources 4. Forms/ VisionTree Overview 5. Social Media/ Clinical Coordinating Department, Will show video showcasing Dr. Schoen promoting FORTE Questions and Answers	Sarah Camden, MS, Assistant Project Manager Christine Lorson, RN, BSN, FORTE Education and Communication Specialist
3:45 p.m.-4:00 p.m.	Part III: FORTE Study is user friendly 6. Funding / User Friendly Study 7. Call to Action Questions and Answers	Robert Schoen, MD, MPH, Principal Investigator/ Study Chair

The NRG Oncology New Investigator
Committee presents:

#NRG2021



Elise C. Kohn, MD
NCI CTEP

Welcome Remarks;
Distinguishing LOI/Concept;
Science Rationale;
How to Develop Your Idea;
Communications;
Biomarker Definitions

LOI/Concept Development Nuts & Bolts

Thursday, January 28, 2021
10:30 am - 12:30 pm EST



Charles Kunos, MD, PhD
NCI CTEP

Reviewing
Identification of
Potential Agents -
CTEP & Beyond;
Preclinical Prerequisites



Masha Kocherginsky, PhD
Northwestern, University

Statistical Considerations
for Clinical Trial Design



Nancy Soto
NRG Oncology

NRG Oncology
-specific Processes
for LOI/Concept
Development



Vinai Gondy, MD
Northwestern University

Pathway to Trial
Development:
Lessons Learned

Session to be followed by breakout group networking sessions from
12:30 pm - 1:15 pm EST - Listed on the Meeting agenda as
"New Investigators Networking Luncheon BYOL"



NRG ONCOLOGY WINTER PLENARY KEYNOTE

THURSDAY, JANUARY 28, 2021 – 3:00PM – 4:00PM ET

Welcome

Mitch Machtay, MD
Presiding Group Chair (Interim)

Federal Funding Landscape

Deborah Watkins Bruner, RN, PhD
NRG NCORP Contact PI

NRG Oncology Portfolio Updates

NRG Developmental Therapeutics Portfolio

Roisin E. O'Cearbhail, MD
NRG Developmental Therapeutics Committee Chair

NRG Genitourinary Cancer Portfolio

Felix Feng, MD
NRG Genitourinary Cancer Committee Chair

NRG Breast Cancer Portfolio

Elftherios Mamounas, MD, MPH
NRG Breast Cancer Committee Chair



AGENDA
NCORP TOWN HALL
Friday, January 29, 2021
10:00 – 11:30am EST

10:00 – 10:15am	Welcome NRG NCORP Updates	Deb Bruner, PhD, RN, NRG NCORP PI
10:15 – 10:30am	Mentorship opportunities	Joan Walker, MD, NCORP PI
10:30 – 10:40am	Q&A – Open Discussion	
10:40 – 10:45am	Introduction of NCI speakers	Deb Bruner, PhD, RN, NRG NCORP PI
10:45 – 10:55am	NCI NCORP Update	Sandra Russo, MD, Community Oncology and Prevention Trials Research Group, DCP
10:55 – 11:05am	NCI CCDR Update	Kathleen Castro, RN, MS, Nurse Consultant, Office of the Associate Director of the Healthcare Delivery Research Program
11:05 – 11:25am	Q&A – Open Discussion – chat moderators	
11:25 – 11:30am	Closing Remarks	Deb Bruner/Joan Walker

#NRG2021



WINTER 2021
VIRTUAL MEETING
Jan. 28 - 30, 2021



Norman Wolmark, MD

**NRG Group Chair
& Contact PI**



Robert Mannel, MD

**NRG Group Chair
& Board Chairman**



**Mitchell Machtay,
MD**

**Presiding Group
Chair (Interim)**



Walter Curran, Jr., MD

Honored Speaker

NRG Oncology General Session

**Friday, January 29, 2021
12:15 pm - 1:15 pm EST**



David Miller, MD

**Deputy Group Chair for
Membership**



Deborah Watkins Bruner, RN, PhD

**NCORP Research Base
Contact PI**



James Dignam, PhD

Group Statistician



Harry Bear, MD

**Deputy Group Chair,
Communications & Publications**



Richard Jordan, DDS, PhD

Biospecimen Bank Grant Co-PI

NRG Oncology General Session

**Friday, January 29
12:15-1:15pm ET**

Opening

Mitchell Machtay, MD
NRG Oncology Presiding Group Chair (Interim)

NRG Research Center Update

Mitchell Machtay, M.D.
Deputy Group Chair, Research

NRG Membership Update

David Miller, M.D.
Deputy Group Chair for Membership

NRG NCORP Research Base Update

Deborah Watkins Bruner, RN, Ph.D.
NCORP Research Base Contact PI

**NRG Communications &
Publications**

Harry Bear, M.D.
Deputy Group Chair, Communications &
Publications

NRG Biospecimen Bank Update

Richard Jordan, DDS, Ph.D.
Biospecimen Bank Grant Co-PI

**NRG Statistical and Data Management
Center Update**

James Dignam, Ph.D.
Group Statistician

Closing Remarks

Mitchell Machtay, MD
NRG Oncology Presiding Group Chair (Interim)



Workshop Agendas (Non-CME)

For CME agendas see Program Book



GI Non-Colorectal Cancer SubCommittee Agenda

Date: Saturday, January 30, 2021
Start Time: 10:45 am- 12:15 PM EST
Non-Colorectal Chair: Ted Hong, MD
Non-Colorectal Co-Chair: David Ilson, MD, PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Appreciate the eligibility criteria and hypotheses being explored in current and upcoming GI Onc clinical trials

Meeting AGENDA

Discussion/Study Information

Introduction and Opening Remarks

Speaker

Ted Hong, MD
David Ilson, MD, PhD

Review of New Concepts, Upcoming and Active Trials

LIVER STUDIES

RTOG 1112	Phase III RCT of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in HCC	Laura Dawson, MD
NRG GI003	Phase III RCT of Protons vs. Photons for HCC	Ted Hong, MD
S1815	A Phase III RCT of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers	Khalid Matin, MD
NRG GI2022	Ablative RT +/- checkpoint inhibition in IHCC	Eugene Koay, MD

ESOPHAGOGASTRIC STUDIES

NRG GI006	Phase III RCT of Protons vs. Photons for Esophageal Carcinoma	Steven Lin, MD
NRG GI007	Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for Surgery	Geoff Ku, MD
EA2183	Rand phase II evaluating consolidative radiation + immunotherapy during first-line systemic therapy in patients with oligometastatic esophagogastric cancer	Kimberly Mak, MD
S2009	Phase II/III Randomized trial of pembrolizumab with or without cabozantinib for third line treatment of patients with advanced PD-L1+ gastric and GE junction cancer	Sam Klempner, MD
EA2174	A phase II study of peri-operative nivolumab and ipilimumab in patients with locoregional esophageal and gastroesophageal junctional adenocarcinoma	Evan Wuthrick

ANAL CANCER STUDIES

EA2165	Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer	Paul Romesser, MD
EA2182	A Randomized Phase II Study of De-intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)	Prajnan Das, MD

GI Colorectal Cancer SubCommittee Agenda

Date: Saturday, January 30, 2021
Time: 9:00 – 10:30 am EST
Colorectal Chair: Thomas George, MD, FACP
Colorectal Co-Chair: Scott Kopetz, MD, PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Appreciate the eligibility criteria and hypotheses being explored in current and upcoming GI Onc clinical trials

Discussion/Study Information		Speaker
Introduction and Opening Remarks		Thomas George, MD Scott Kopetz, MD, PhD
Review of New Concepts, Upcoming and Active Trials		
Neuroendocrine Tumors		
	NCTN Portfolio of NET Studies	Heloisa Soares, MD
Adjuvant Colon Studies		
NRG-GI005	cfDNA as a decision tool for stage II colon cancer treatment	Kyle Van Morris, MD
NRG-GI008 (CIRCULATE-US)	cfDNA as decision tool for stage III colon cancer treatment	Arvind Dasari, MD
A021502 (ATOMIC)	MSI-H colon adjuvant trial FOLFOX +/- Atezolizumab	Asha Dhanarajan, MD
S0820 (PACES)	Eflornithine & Sulindac for polyp prevention after CRC	Jenny Dorth, MD
Metastatic CRC Studies		
NRG-CR2003 (ERASure)	Update on Oligometastatic CRC Total Ablative Therapy	Paul Romesser, MD Kate Hitchcock, MD, PhD Eric Miller, MD, PhD
NRG-GI004/S1610 (COMMIT)	MSI-H mCRC 1L Immunotherapy Study	Caio Rocha Lima, MD
A021703 (SOLARIS)	Vitamin D supplementation in untreated mCRC	Christina Wu, MD
S1613	HER2 Amplified mCRC Randomized Phase II Study of Pertuzumab and Trastuzumab vs Cetuximab and Irinotecan	Marwan Fakih, MD
Rectal Cancer Studies		
A022003/NRG-CR1861 (JANUS)	Non-operative rectal cancer study concept	William Hall, MD
NRG-GI002 (TNT) and CR2064	TNT Trial and national rectal cancer studies	Thomas George, MD
New Early Phase Rectal Cancer Concepts	ATR inhibition	Terry Williams, MD, PhD Eric Miller, MD, PhD
	IDO inhibition	Haeseong Park, MD, MPH Matthew Ciorba, MD

Head and Neck Workshop

Date: Friday, January 29, 2021
Start and End Time: 1:30 – 3:30 PM ET
Chair: Quynh-Thu Le, MD, FACP, FASTRO
Co-Chair: Erich Sturgis, MD, MPH; Stuart Wong, MD

Learning Objectives:

Following this activity, participants will be better able to:

1. Develop new head and neck cancer trials to be conducted through the NRG-Oncology network, specifically those testing (1) the addition of novel systemic therapies (chemotherapy, targeted therapy, immunotherapy) to radiation, (2) novel surgical or radiation approaches, (3) novel imaging approaches or (4) strategies to mitigate treatment related toxicity
2. Develop strategies to enable effective patient enrollment on these trials and proper collection, submission and/or evaluation of the required patient data.
3. Apply the results of completed NRG Oncology trials to daily treatment decision making in order to optimize patient care

WORKSHOP AGENDA

A. Head and Neck portfolio overview

Quynh-Thu Le, MD

B. Actively developing studies

- **HN009 trial (formerly 1937 concept)** Phase II-III HD vs. Weekly cisplatin in high risk LA HNSCC (HPV- and HPV+ cohorts) Paul Harari, MD
- **HN2004 concept:** Phase II of T-DM1 +/- Atezo in recurrent/metastatic HER2 positive SDC and SGC Alan Ho, MD
- **HN2115 LOI (formerly 1936):** Single-arm phase II trial of chemo-immunoselection for salvage surgery (SS) with life-long morbidity in recurrent/persistent PD-L1 enriched SCCHN Nabil Saba, MD
- **HN2001 concept:** Phase II-III of placebo vs. adjuvant IO in LA NPC with persistently detectable EBV DNA Nancy Lee, MD
- **Proposed trial:** HypoPORT: A randomized phase II-III trial of hypofractionated PORT for HNC Shlomo Koyfman, MD
Matthew Ward, MD

C. Review on active studies

Actively accruing trials

RTOG 1216	RT+cisplatin vs. RT+docetaxel+cetuximab vs. RT+cisplatin+atezolizumab for “high risk” resected HNSCC (Phase IIIR)	Julie Bauman Paul Harari David Rosenthal
NRG-HN006	Phase II-III SLN Biopsy vs. END in T1-2N0 oral cavity cancer	Stephen Lai
NRG-HN007	Phase III Gem/Cis vs. Gem/Cis/Nivo in 1 st line rec/met NPC	Brigitte Ma
NRG-HN008	Phase I RT + DNA-PK inhibitor in High risk LA HNSCC	Maura Gillison Michael Samuels

RTOG 3507	Phase IIR - ReRT +/- Pembrolizumab in Locoregionally recurrent HNSCC	Stuart Wong
RTOG 1008	Concurrent radiation-chemotherapy for high-grade salivary gland cancer (Phase II-IIIR)	Cristina Rodriguez
NRG-HN001	Individualized NPC treatment based on post-RT EBV DNA (Phase III)	Nancy Lee
NRG-HN004	Phase II-IIIR RT+ Cetuximab vs. RT + PD-L1 antibody in patients who cannot tolerate cisplatin with locally advanced HNSCC	Loren Mell
NRG-HN005	Phase II-IIIR of reduced field RT +/- systemic therapy for good risk HPV(+) cancer	Sue Yom

D. Report on publications and protocols closed to active accrual

Quynh-Thu Le, MD

Recently completed trials

NRG HN003	Phase I of Adjuvant Chemoradiotherapy +/- Pembrolizumab in High Risk, HPV(-) HNSCC	Julie Bauman
RTOG 3504	Phase IR of CRT +/- Nivolumab in intermediate/high risk HNSCC	Quynh-Thu Le
NRG HN002	Phase IIR dose de-escalation study for Human Papillomavirus-Positive, Good-Prognosis Advanced-Stage Oropharyngeal Cancer	Sue Yom
RTOG 0912	Phase IIR of Concurrent radiation + chemotherapy + pazopanib for Anaplastic Thyroid Cancer	Eric Sherman
RTOG 3501	Phase IIR of CRT +/- Lapatinib in high risk stage III-IV HNSCC	Stuart Wong

E. New Investigator

Shlomo Koyfman, MD

F. EA3191 trial: Phase II adjuvant reirradiation vs pembro for recurrent/second primary HNSC

Zain Husain, MD

QUESTIONS / DISCUSSION



Scientific Core Committees

NRG Oncology Health Disparities Committee
Thursday, January 28 (Virtual Meeting)
10am – 12pm ET
Agenda

Chairs: *Chanita Hughes Halbert, PhD*
 Kate Yeager, PhD, RN, MS

- | | |
|---------------------|---|
| 10:00 - 10:10 am | Welcome/Announcements - Kate Yeager / Chanita Hughes Halbert |
| 10:10 – 10:30 am | Committee Leadership Updates: Introduction of the new Chair
Jennifer Wenzel, PhD, RN, CCM, FAAN |
| 10:30 – 10:45 am | Rural capacity and CCDR accrual barriers - Shellie Ellis |
| 10:45 – 11:00 am | HDC Rural Survey of NRG Members summary and Rural Research SIG updates - Kate Yeager/
Na Tosha Gatson |
| 11:00 – 11:30 am | HDC Research Concept Development SIG update - Chanita Hughes Halbert |
| 11:30 – 11:45 am | Research Implementation (Education/Training/Mentorship) SIG update - Kathie-Ann Joseph,
William Robinson |
| |
Clinical Trial Enrollment Updates - <i>Statistics/Metrics</i> - <i>SDMC Reports</i> -William
Robinson; Reena Cecchini |
| |
Education/Training- Kathie-Ann Joseph |
| 11:45 – 11:55 am | Older Adult Research SIG update – William Tew |
| 11:55 am – 12:00 pm | Closing remarks/Summary/Adjournment |

Date: Friday, January 29, 2021
Start and End Time: 8:00 am – 10:00 am
Chair: Jeff Michalski, MD
Co-Chairs: Ivy Petersen, MD and Evan Wuthrick, MD
Participation Link: TBA

VIRTUAL MEETING AGENDA

- 8:00 – 8:05** **Welcome / Introduction** Jeff Michalski, MD
- 8:05 – 8:35** **3rd Annual RO Symposium Theme “Radiopharmaceutical Therapy (RPT)” hosted by Evan Wuthrick, MD, NRG Radiation Oncology Committee**
- **Amir Iravani, MD** – Asst. Professor/ Division of Nuclear Medicine Mallinckrodt Institute of Radiology at Washington Unvi. School of Medicine, St. Louis
Title: Overview of opportunities of RPT in the NCTN
 - Radiation dosimetry in RPT trials
 - **Charles Kunos, MD, PhD** – Medical Officer, Investigational Drug Branch Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health
Title: NIH Commitment – ETCTN
 - Vision - how these RPT trials will be done
 - Development in clinical trials
 - **Hiram Gay, MD– Department of Radiation Oncology, Washington University of Saint Louis**
Title: PI Update on NCI Protocol #10301
 - A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
 - **Jyoti Malhotra, MD, MPH – Rutgers Cancer Institute of New Jersey**
Title: PI Update on NCI Protocol #10302
 - Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
-

8:35 – 8:40	NRG Oncology Updates	Jeff Michalski, MD/Evan Wuthrick, MD/Ivy Petersen, MD
	<ul style="list-style-type: none"> a. NRG Oncology Meeting agenda: NRG Meeting Agenda b. NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study (Create a bank of clinical data, research blood specimens & radiological images for future research.) <ul style="list-style-type: none"> • Activated on 5/21/2020 – Targeting 2,000 patient enrollment • Capitation by Credited Group (NCTN, NCORP or ETCTN) 	
8:40– 8:50	<u>Update on NCTN Cooperative Cores</u>	
	a. Imaging and Radiation Oncology Core (IROC) RT Update For NRG Trials	Stephen Kry ,MD Denise Manfredi,BS
	b. Imaging and Radiation Oncology Core (IROC) Imaging Update for NRG Trials	Michael Boss, PhD Mark Rosen, MD
8:50– 8:55	Overview of Medical Physics	
	a. Overview of Medical Physics	Ying Xiao,PhD Stan Benedict, PhD
	b. NCTN Physics Committee	Ceferino Obcema, PhD
9:00 – 9:05	Proton Sites Credentialing	Paige Taylor, MS
	MR Guided Linac	Jeff Michalski, MD Evan Wuthrick, MD
9:05 – 9:57	<u>Disease Site Liaisons Reports</u>	
	a. H&N (8 min.)	Sue Yom, MD / Min Yao, MD
	b. Brain (8min.)	Christina Tsien, MD / Tong Wang, MD
	c. Breast (8 min.)	Steven Chmura, MD / Simona Shaitelman, MD
	d. Gyn (8 min.)	Sushil Beriwal, MD / Mark Bernard, MD
	e. GI (8 min.)	Evan Wuthrick, MD / Emma Holliday, MD
	f. GU (8 min.)	Dan Krauss, MD / Hiram Gay, MD
	g. Lung (8 min.)	Charles Simone, MD / Pending
	h. Sarcoma (4 min.)	Philip Wong, MD / Dian Wang, MD
9:57 – 10:00	Other Business / Q & A Discussion	



Institutional Accrual

Accrual For Agenda Book from 1/1/2020 to 12/31/2020 Run Date: 1/13/2021				
NRG Main Member (Network)	CTEP ID	Accrued to NRG Studies and Credited to NRG	Accrued to Non-NRG NCTN Studies and Credited to NRG	Total
21st Century Oncology MHP - Farmington	MI310	19	7	26
Allan Blair Cancer Centre	11076	10	0	10
Allegheny General Hospital	PA009	15	45	60
AMITA Health Alexian Brothers Medical Center	IL280	4	5	9
Arizona Center for Cancer Care-Peoria	AZ127	3	10	13
Aurora NCI Community Oncology Research Program	AURORA	16	15	31
Avera Cancer Institute	SD021	5	13	18
Banner University Medical Center - Tucson	AZ017	24	9	33
Baptist Health Cancer Research Network	BHCRN	3	18	21
Bay Area Tumor Institute NCORP	BATI	0	0	0
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	TX041	0	10	10
Baystate Medical Center	MA004	0	6	6
Berkshire Medical Center - Cancer Center	MA125	0	4	4
Boston Medical Center	MA043	4	391	395
Cancer Research Consortium of West Michigan NCORP	CRCWM	11	3	14
Cancer Research for the Ozarks NCORP	OZARKS	18	12	30
Cancer Research of Wisconsin and Northern Michigan Consortium	CROWN	27	10	37
Cancer Trials Ireland	ICORG	5	0	5
Carle Cancer Center NCI Community Oncology Research Program	CARLE	4	0	4
Carolinas Medical Center/Levine Cancer Institute	NC042	5	1	6
Catholic Health Initiatives NCORP	CORA	15	4	19
Cedars-Sinai Medical Center	CA016	3	5	8
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont	11065	2	0	2
Chinese University of Hong Kong-Prince of Wales Hospital	34003	7	0	7
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)	11073	6	0	6
CHUM - Centre Hospitalier de l'Universite de Montreal	11062	9	0	9
City of Hope Comprehensive Cancer Center	CA043	7	0	7
CIUSSSEMTL-Hopital Maisonneuve-Rosemont	11060	4	0	4
Columbia University Minority Underserved NCORP	COLUMBIA	1	11	12
Columbus NCI Community Oncology Research Program	COLUMBUS	13	3	16
Community Cancer Center North	IN006	2	9	11
Cooper Hospital University Medical Center	NJ036	3	24	27
Covenant Medical Center-Lakeside	TX054	0	1	1
Cross Cancer Institute	11132	10	0	10
CWRU Case Comprehensive Cancer Center LAPS	LAPS-OH029	83	28	111
Dana-Farber / Partners CancerCare LAPS	LAPS-MA036	16	4	20
Danbury Hospital	CT030	4	4	8
Dartmouth College - Norris Cotton Cancer Center LAPS	LAPS-NH012	10	10	20
Dayton NCI Community Oncology Research Program	DAYTON	1	4	5

Delaware/Christiana Care NCI Community Oncology Research Progra	CHRISTIANA	34	4	38
Dell Seton Medical Center at The University of Texas	TX063	0	0	0
Duke University - Duke Cancer Institute LAPS	LAPS-NC010	3	0	3
Edward Hospital/Cancer Center	IL104	8	14	22
Einstein Medical Center Philadelphia	PA094	0	0	0
Emory University - Winship Cancer Institute LAPS	LAPS-GA005	23	13	36
Essentia Health NCI Community Oncology Research Program	ESSENTIA	1	0	1
Fox Chase Cancer Center	PA086	8	12	20
Fred Hutchinson Cancer Research Center LAPS	LAPS-WA008	11	0	11
Froedtert and the Medical College of Wisconsin LAPS	LAPS-WI013	23	7	30
Geisinger Cancer Institute NCI Community Oncology Research Progra	GEISINGER	13	9	22
Georgia Cares Minority Underserved NCORP	GACARES	21	3	24
Georgia NCI Community Oncology Research Program	GEORGIA	20	35	55
Greater Baltimore Medical Center	MD018	4	19	23
Gulf South Minority Underserved NCORP	GULFSOUTH	16	3	19
Hackensack University Medical Center	NJ022	2	1	3
Hartford Hospital	CT009	4	5	9
Hawaii Minority Underserved NCORP	HAWAII	4	77	81
Heartland Cancer Research NCORP	HEARTLAND	37	6	43
Henry Ford Hospital	MI026	10	116	126
Houston Methodist Hospital	TX036	5	9	14
Indiana University/Melvin and Bren Simon Cancer Center	IN007	8	27	35
Iowa-Wide Oncology Research Coalition NCORP	IWORC	5	28	33
James A. Haley Veterans Affairs Hospital	FL064	0	0	0
Jewish General Hospital	11116	5	0	5
JHU Sidney Kimmel Comprehensive Cancer Center LAPS	LAPS-MD017	2	13	15
Juravinski Cancer Centre at Hamilton Health Sciences	11183	4	0	4
Kaiser Permanente NCI Community Oncology Research Program	KAISER	35	52	87
Kaiser Permanente-Gaithersburg Medical Center	MD198	0	16	16
Kantonsspital Aarau	67029	1	0	1
Lahey Hospital and Medical Center	MA017	3	6	9
Lankenau Medical Center	PA125	8	1	9
Legacy Good Samaritan Hospital and Medical Center	OR013	6	0	6
Loyola University Medical Center	IL017	8	0	8
MaineHealth Cancer Care Network	MAINE	18	26	44
Mayo Clinic LAPS	LAPS-MN026	14	4	18
Medical University of South Carolina Minority Underserved NCORP	MUSC	16	7	23
MedStar Franklin Square Medical Center/Weinberg Cancer Institute	MD029	9	15	24
Memorial Sloan-Kettering Cancer Center LAPS	LAPS-NY016	38	18	56
Mercy Cancer Center - Sacramento	CA729	2	3	5
Metro Minnesota Community Oncology Research Consortium	METROMIN	30	22	52
Miami Cancer Institute	FL078	28	1	29
Michigan Cancer Research Consortium NCORP	MCRC	26	0	26
Michigan State University Clinical Center	MI038	0	1	1
Midwestern Regional Medical Center	IL120	6	11	17
Moffitt Cancer Center	FL065	14	37	51
Montana Cancer Consortium NCORP	MONTANA	12	1	13
Montefiore Minority Underserved NCORP	MONTEFIORE	12	3	15
Mount Sinai Hospital	NY021	5	7	12

National Cancer Centre Singapore	47005	1	0	1
National Institutes of Health Clinical Center	MD004	0	0	0
NCORP of the Carolinas (Greenville Health System NCORP)	GREENVILLE	20	20	40
Nevada Cancer Research Foundation NCORP	NCRF	0	0	0
New Mexico Minority Underserved NCORP	NEWMEXICO	22	28	50
New York-Presbyterian/Brooklyn Methodist Hospital	NY075	5	0	5
NorthShore University HealthSystem-Evanston Hospital	IL018	7	5	12
Northwell Health NCORP	NORTHWELL	0	14	14
Northwestern Medicine Cancer Center Warrenville	IL387	12	35	47
Northwestern University LAPS	LAPS-IL036	13	24	37
Norton Hospital Pavilion and Medical Campus	KY049	8	3	11
Odette Cancer Centre- Sunnybrook Health Sciences Centre	11118	9	0	9
Ohio State University Comprehensive Cancer Center LAPS	LAPS-OH007	23	6	29
Orlando Health Cancer Institute	FL020	4	7	11
Ottawa Hospital and Cancer Center-General Campus	11025	2	0	2
Pacific Cancer Research Consortium NCORP	PCRC	16	3	19
Parkview Regional Medical Center	IN181	4	23	27
Peter MacCallum Cancer Centre	3003	1	0	1
Piedmont Hospital	GA027	2	7	9
ProMedica Flower Hospital	OH012	5	3	8
Puerto Rico Minority Underserved NCORP	PUERTORICO	9	0	9
Rabin Medical Center	40021	0	0	0
Reading Hospital	PA107	5	6	11
Rhode Island Hospital	RI005	7	0	7
Roswell Park Cancer Institute LAPS	LAPS-NY158	15	3	18
Rush University Medical Center	IL043	2	8	10
Rutgers Cancer Institute of New Jersey	NJ066	16	21	37
Saint Joseph Hospital - Orange	CA087	2	9	11
Saint Joseph's Hospital and Medical Center	AZ009	3	11	14
Saitama Medical University International Medical Center	42061	12	0	12
Sanford NCI Community Oncology Research Program of the North Ce	SANFORD	11	13	24
Saskatoon Cancer Centre	11120	8	0	8
Seoul National University Hospital	43002	16	0	16
Southeast Clinical Oncology Research Consortium NCORP	SCOR	42	12	54
Stanford Cancer Institute Palo Alto	CA141	16	0	16
Staten Island University Hospital	NY035	0	0	0
Stony Brook University Medical Center	NY184	6	20	26
Stroger Hospital of Cook County Minority Underserved NCORP	STROGER	17	0	17
Summa Health System - Akron Campus	OH055	2	8	10
Sun Yat-sen University Cancer Center	60021	19	0	19
Sutter Cancer Research Consortium	SUTTER	12	45	57
Tel Aviv Sourasky Medical Center	40019	0	0	0
The Community Hospital	IN044	0	12	12
The James Graham Brown Cancer Center at University of Louisville	KY002	8	10	18
The Research Institute of the McGill University Health Centre (MUHC)	11318	10	0	10
Thomas Jefferson University Hospital LAPS	LAPS-PA121	22	22	44
Thompson Cancer Survival Center	TN038	1	2	3
Tibor Rubin VA Medical Center	CA041	0	0	0
Tom Baker Cancer Centre	11134	8	0	8

Trinity Cancer Care Center	ND026	0	14	14
Tulane University Health Sciences Center	LA001	1	3	4
UC Davis Comprehensive Cancer Center LAPS	LAPS-CA189	4	0	4
UC Irvine Health/Chao Family Comprehensive Cancer Center	CA088	7	24	31
UC San Diego Moores Cancer Center	CA249	18	3	21
UCLA / Jonsson Comprehensive Cancer Center	CA006	2	4	6
UCSF Medical Center-Mount Zion	CA136	12	123	135
UMass Memorial Medical Center - Memorial Division	MA009	0	0	0
UNC Lineberger Comprehensive Cancer Center LAPS	LAPS-NC007	4	26	30
University Health Network-Princess Margaret Hospital	11030	19	0	19
University of Alabama at Birmingham / Deep South Research Consortium	LAPS-AL002	22	28	50
University of Arkansas for Medical Sciences	AR006	9	7	16
University of Chicago Comprehensive Cancer Center LAPS	LAPS-IL057	18	29	47
University of Cincinnati/Barrett Cancer Center	OH070	27	120	147
University of Colorado Cancer Center LAPS	LAPS-CO070	18	69	87
University of Connecticut	CT002	0	0	0
University of Florida Health Science Center - Gainesville	FL015	1	77	78
University of Illinois	IL040	3	14	17
University of Iowa/Holden Comprehensive Cancer Center	IA018	18	16	34
University of Kansas Cancer Center - MCA Rural MU NCORP	KANSAS	31	0	31
University of Kentucky/Markey Cancer Center	KY010	7	15	22
University of Maryland/Greenebaum Cancer Center	MD015	22	13	35
University of Miami Miller School of Medicine-Sylvester Cancer Center	FL028	8	17	25
University of Michigan Comprehensive Cancer Center LAPS	LAPS-MI014	7	12	19
University of Minnesota/Masonic Cancer Center	MN022	5	0	5
University of Mississippi Medical Center	MS005	0	4	4
University of Nebraska Medical Center	NE003	5	2	7
University of Oklahoma Health Sciences Center LAPS	LAPS-OK003	96	81	177
University of Pennsylvania/Abramson Cancer Center	PA075	8	6	14
University of Pittsburgh Cancer Institute LAPS	LAPS-PA015	23	13	36
University of Rochester LAPS	LAPS-NY167	29	7	36
University of South Alabama Mitchell Cancer Institute	AL068	2	10	12
University of Tennessee - Knoxville	TN021	0	8	8
University of Tennessee Health Science Center	TN030	0	0	0
University of Texas Health Science Center at San Antonio	TX059	6	13	19
University of Texas MD Anderson Cancer Center LAPS	LAPS-TX035	50	15	65
University of Texas Medical Branch	TX045	0	24	24
University of Texas Southwestern Medical Center LAPS	LAPS-TX011	27	4	31
University of Utah - Huntsman Cancer Institute LAPS	LAPS-UT003	11	3	14
University of Vermont and State Agricultural College	VT004	9	1	10
University of Virginia Cancer Center	VA009	7	8	15
University of Wisconsin Carbone Cancer Center LAPS	LAPS-WI020	14	11	25
Upstate Carolina Consortium Community Oncology Research Program	UPSTATE	35	4	39
USC Norris Comprehensive Cancer Center LAPS	LAPS-CA011	3	60	63
Vanderbilt University - Ingram Cancer Center LAPS	LAPS-TN008	4	3	7
VCU Massey Cancer Center Minority Underserved NCORP	VCU	3	39	42
Veterans Administration Hospital	FL051	0	0	0
Wake Forest University Health Sciences	NC002	12	1	13
Walter Reed National Military Medical Center	MD001	3	0	3

Washington University - Siteman Cancer Center LAPS	LAPS-MO011	43	14	57
Wayne State University - Karmanos Cancer Institute LAPS	LAPS-MI020	26	35	61
WellSpan Health-York Hospital	PA047	3	16	19
West Virginia University Charleston Division	WV004	7	8	15
West Virginia University Healthcare	WV025	7	17	24
Western States Cancer Research NCORP	WESTERN	12	27	39
William Beaumont Hospital-Royal Oak	MI005	13	61	74
Wisconsin NCI Community Oncology Research Program	WINCORP	8	17	25
Women and Infants Hospital	RI012	31	10	41
Women's Cancer Center of Nevada	NV049	32	0	32
Yale University - Yale Cancer Center LAPS	LAPS-CT018	9	5	14
Yonsei University Health System-Severance Hospital	43027	0	0	0

NRG Oncology wishes to acknowledge the following sponsors and exhibitors:

Platinum



Silver



Exhibitors

American College of Radiology

AstraZeneca

Caris Life Sciences

GSK Medical

Merck

Natera, Inc.

Seagen, Inc.

Exhibit Dates/Hours:

Thursday, Jan 28, 2021 and Friday, Jan 29, 2021

9 am - 5 pm EST

Please take the time to visit the virtual exhibit booths on the Virtual Attendee Hub

PLATINUM SPONSOR

Seagen, Inc.

Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.

SILVER SPONSOR

GSK Medical

GSK Medical is focused on maximizing patient survival through transformational medicines. GSK's oncology pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality.



NRG Oncology Winter 2021 Virtual Meeting - January 28-30, 2021

NRG Oncology would like to recognize and thank its commercial supporters for Independent Medical Educational Support associated with the NRG Oncology Winter 2021 Virtual Meeting.

NRG Oncology Commercial Supporters



AbbVie
Clovis
Eli Lilly
Genomic/Exact Sciences
Novocure
Pfizer
Seattle Genetics